Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

Eric J. Small,Rahul Aggarwal,Verena Friedl,Alana S. Weinstein,George Thomas,Lawrence D. True,Adam Foye,Tomasz M. Beer,Matthew Rettig,Martin E. Gleave,Christopher H Evans,Joshi J. Alumkal,Robert E. Reiter,Primo N. Lara,Kim N. Chi,Felix Y. Feng,Adina M. Bailey,Josh Stuart,Jiaoti Huang

Intermediate atypical carcinoma (IAC): A discrete subtype of metastatic castration-resistant prostate cancer (mCRPC) suggesting that treatment-associated small cell/neuroendocrine prostate cancer (t-SCNC) may evolve from mCRPC adenocarcinoma (adeno)—Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).

2020

Eric J. Small
Rahul Aggarwal
Verena Friedl
Alana S. Weinstein
George Thomas
Lawrence D. True
Adam Foye
Tomasz M. Beer
Matthew Rettig
Martin E. Gleave
Christopher H Evans
Joshi J. Alumkal
Robert E. Reiter
Primo N. Lara
Kim N. Chi
Felix Y. Feng
Adina M. Bailey
Josh Stuart
Jiaoti Huang

158Background: A subset of mCRPC patients (pts) that develop resistance to next-gen androgen signaling inhibitors are subsequently found to harbor t-SCNC. We have undertaken a longitudinal prospect...

Keywords:

Castration
Oncology
Prostate cancer
Pathology
Adenocarcinoma
Carcinoma
Internal medicine
Cell
Medicine
castration resistant
west coast
Androgen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations